Skip to content

At ACADIA, we are committed to improving the lives of patients with neurological and related central nervous system disorders.

About Us

ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. More »



News

April 01, 2014
ACADIA Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference on April 8, 2014

March 05, 2014
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences

More News »

Product Candidates

We have a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.   More »


 

Company Information

Investor's Kit Learn More: Pimavanserin Phase III Program for Parkinson's Disease Psychosis »
Investor Webcasts Investor Webcasts »
Email Updates Email Updates »